Lan Tian, Liu Weihua, Xie Xi, Xu Suowen, Huang Kaipeng, Peng Jing, Shen Xiaoyan, Liu Peiqing, Wang Lijing, Xia Pu, Huang Heqing
Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Mol Endocrinol. 2011 Dec;25(12):2094-105. doi: 10.1210/me.2011-0095. Epub 2011 Oct 13.
Diabetic nephropathy is characterized by accumulation of glomerular extracellular matrix proteins, such as fibronectin (FN). Here, we investigated whether sphingosine kinase (SphK)1 pathway is responsible for the elevated FN expression in diabetic nephropathy. The SphK1 pathway and FN expression were examined in streptozotocin-induced diabetic rat kidney and glomerular mesangial cells (GMC) exposed to high glucose (HG). FN up-regulation was concomitant with activation of the SphK1 pathway as reflected in an increase in the expression and activity of SphK1 and sphingosine 1-phosphate (S1P) production in both diabetic kidney and HG-treated GMC. Overexpression of wild-type SphK1 (SphK(WT)) significantly induced FN expression, whereas treatment with a SphK inhibitor, N,N-dimethylsphingosine, or transfection of SphK1 small interference RNA or dominant-negative SphK1 (SphK(G82D)) abolished HG-induced FN expression. Furthermore, addition of exogenous S1P significantly induced FN expression in GMC with an induction of activator protein 1 (AP-1) activity. Inhibition of AP-1 activity by curcumin attenuated the S1P-induced FN expression. Finally, by inhibiting SphK1 activity, both N,N-dimethylsphingosine and SphK(G82D) markedly attenuated the HG-induced AP-1 activity. Taken together, these results demonstrated that the SphK1 pathway plays a critical role in matrix accumulation in GMC under diabetic condition, suggesting that the SphK1 pathway could be a potential therapeutic target for diabetic nephropathy.
糖尿病肾病的特征是肾小球细胞外基质蛋白(如纤连蛋白,FN)的积累。在此,我们研究了鞘氨醇激酶(SphK)1通路是否与糖尿病肾病中FN表达升高有关。在链脲佐菌素诱导的糖尿病大鼠肾脏以及暴露于高糖(HG)环境的肾小球系膜细胞(GMC)中检测了SphK1通路和FN表达。在糖尿病肾脏和HG处理的GMC中,FN上调与SphK1通路的激活同时出现,表现为SphK1的表达和活性增加以及鞘氨醇-1-磷酸(S1P)生成增多。野生型SphK1(SphK(WT))的过表达显著诱导FN表达,而用SphK抑制剂N,N-二甲基鞘氨醇处理、转染SphK1小干扰RNA或显性负性SphK1(SphK(G82D))则消除了HG诱导的FN表达。此外,添加外源性S1P显著诱导GMC中FN表达,并诱导激活蛋白1(AP-1)活性。姜黄素抑制AP-1活性减弱了S1P诱导的FN表达。最后,通过抑制SphK1活性,N,N-二甲基鞘氨醇和SphK(G82D)均显著减弱了HG诱导的AP-1活性。综上所述,这些结果表明SphK1通路在糖尿病条件下GMC的基质积累中起关键作用,提示SphK1通路可能是糖尿病肾病的一个潜在治疗靶点。